A meta-analysis taking into account 15 studies published between 2001 and 2013 was reported by Wang et al., which demonstrated that serum CEA has low sensitivity (18%) and high specificity (93–95%) for malignant and invasive IPMN [35]. The gene discussed is CEACAM5; the disease is pancreatic intraductal papillary-mucinous neoplasm.